Can HÜZMELİ
(Cumhuriyet Üniversitesi Tıp Fakültesi, Sivas, Türkiye)
FERHAN CANDAN
(Cumhuriyet Üniversitesi Tıp Fakültesi, Sivas, Türkiye)
Gökhan BAĞCI
(Cumhuriyet Üniversitesi Tıp Fakültesi, Sivas, Türkiye)
Demet ALAYGUT
(Cumhuriyet Üniversitesi Tıp Fakültesi, Sivas, Türkiye)
Binnur BAĞCI
(Cumhuriyet Üniversitesi Tıp Fakültesi, Sivas, Türkiye)
Esin YILDIZ
(Cumhuriyet Üniversitesi Tıp Fakültesi, Sivas, Türkiye)
Ayse Seker KOCKARA
(Cumhuriyet Üniversitesi Tıp Fakültesi, Sivas, Türkiye)
Mansur KAYATAŞ
(Cumhuriyet Üniversitesi Tıp Fakültesi, Sivas, Türkiye)
Yıl: 2016Cilt: 7Sayı: 5ISSN: 1309-2014Sayfa Aralığı: 695 - 700İngilizce

140 6
Evaluation of 61 Secondary Amyloidosis Patients: A Single-Center Experience from Turkey
Amaç: Sekonder amiloidozlu hastaların demografik, klinik ve laboratuar özelliklerini, hastalık sebeplerini, MEFV gen mutasyonlarını ve mortalite oranlarını değerlendirmek. Gereç ve Yöntem: 2007-2013 arasında Cumhuriyet Üniversitesi, Tıp Fakültesi, Nefroloji kliniğine başvuran böbrek yada rektal doku biyopsisiyle sekonder amiloidoz tanısı alan toplam 61 hasta çalışmaya dahil edildi. Demografik özellikler, sekonder amiloidoz sebepleri, MEFV gen mutasyonları, ve son dönem böbrek yetmezliği (SDBY), renal transplantasyon ve mortalite oranları retrospektif olarak değerlendirildi. Bulgular: Etiyolojik açıdan hastaların %62.2'si (38) FMF, %9.8'i (6) bronşiyektazi ve amfizem, %4.9'u (3) tüberküloz, %3.2'si (2) FMF ve ankilozan spondilit birlikteliği, %1.6'sı (1) FMF ve romatoid artrid birlikteliği, %1.6'sı (1) FMF ve sistemik lupus eritematozus birlikteliği, %1.6'sı (1) osteomiyelit, %1.6'sı (1) septik artrit, %1.6'sı (1) crohn hastalığı, %1.6'sı (1) kolon kanseri, %1.6'sı (1) bronşiyektazi ve tüberküloz birlikteliği, %1.6'sı (1) romatoid artrit ve %6.5'i (4) idiyopatik olarak değerlendirildi. Sekonder amiloidozu olan 47 hastanın 32'sinde (%68) nefrotik düzeyde proteinuri saptandı. Sekonder amiloidozlu 45 hastanın MEFV gen mutasyonları incelendi. Hastaların çoğunda M694V mutasyonu vardı. Şaşırtıcı bir şekilde, 3 vakada heterozigot E148Q mutasyonu saptadık. 12 vaka öldü ve bu hastaların 9'u SDBY'idi. SDBY olan 5 vaka böbrek nakli oldu. Tartışma: Bu çalışmada sekonder AA amiloidoz için en yaygın sebep olarak FMF hastalığını bulduk. Daha büyük yada çok merkezli kohortlarda daha ileri çalışmalar yapılmalıdır
Fen > Tıp > Genel ve Dahili Tıp
DergiAraştırma MakalesiErişime Açık
  • 1. Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol 2006;(6):214-20.
  • 2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;(349):583-96.
  • 3. Kyle RA. Amyloidosis: a convoluted story. Br J Haematol 2001;(114):529-38.
  • 4. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014;(21):221-4.
  • 5. Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012;(142):13580.
  • 6. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amiloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;(358):24-9.
  • 7. Kanat O, Evrensel T, Filiz G, Usta M, Baskan E, Dilek K, et al. Systemic AA amyloidosis and nephrotic syndrome associated with small cell carcinoma of the bladder. Nephrol Dial Transplant 2003;(18):2453-4.
  • 8. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;(1753):11-22.
  • 9. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis. Best Pract Res Clin Haematol 2005;(18):709-27.
  • 10. Pepys MB. Amyloidosis. Annu Rew Med 2006;(57):223-41.
  • 11. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000;(95):3223- 31.
  • 12. Ozdemir O, Sezgin I, Kurtulgan HK, Candan F, Koksal B, Sumer H, et al. Prevalence of known mutations in the MEFV gene in a population screening with high rate of carriers. Mol Biol Rep 2011;(38):3195-200.
  • 13. Koksal B, Nur N, Sari M, Candan F, Acemoglu M, Kocak N, et al. Clinical and molecular analysis of common MEFV gene mutations in familial Mediterranean fever in Sivas population. Biologia 2009;(64):388-93.
  • 14. Ozdemir O, Kayatas M, Cetinkaya S, Yildirim ME, Silan F, Kurtulgan HK, et al. Bcii-RFLP profiles for serum amiloid A1 and mutated MEFV gene prevalence in chronic renal failure patients requiring long-term hemodialysis. Renal Failure 2015;(37):292-6.
  • 15. Shinawi M, Brik R, Berant M, Kasinetz L, Gershoni-Baruch R. Familial Mediterranean fever: high gene frequency and heterogeneous disease among an Israeli- Arab population. J Rheumatol 2000;27:1492-5
  • 16. Livneh A, Langevitz P, Shinar Y, Zaks N, Kastner DL, Pras M, et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 1999; 6:1-6.
  • 17. Gershoni‐Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003;(48):1149- 55.
  • 18. Tuglular S, Yalcinkaya F, Paydas S, Oner A, Utas C, Bozfakioglu S, et al. A retrospective analysis for aetology and clinical findings of 287 secondary amiloidosis cases in Turkey. Nephrol Dial Transplant 2002;(17):2003-5.
  • 19. Zemer D, Livneh A, Pras M, Sohar E. The kidney in familial Mediterranean fever. Contrib Nephrol 1993;(102):187-97.
  • 20. Rocken C, Sletten K. Amyloid in surgical pathology. Virchows Arch 2003;(443):3- 16.
  • 21. Ozen S. Renal amyloidosis in familial mediterranean fever. Kidney Int 2004;(65):1118-27.
  • 22. Mimouni A, Magal N, Stoffman N, Shohat T, Minasian A, Krasnov M, et al. Familial Mediterranean fever: Effects of Genotype and Ethnicity on inflammatory Attacks and Amyloidosis. Pediatrics 2000;(105):e70.
  • 23. Eroglu E, Kocyigit I, Ates O, Unal A, Sipahioglu MH, Akgun H, et al. Mesangial proliferative glomerulonephritis in familial Mediterranean fever patient with E148Q mutation: the first case report. Int Urol Nephrol 2013;(45):591-4.
  • 24. Hüzmeli C, Koçkara AŞ, Candan F, Kayataş M Biopsy Proven Non-Amyloid Glomerular Diseases in Patients With Familial Mediterranean Fever. Journal of Nephrology Research 2015;(1):34-9.
  • 25. Topaloglu R, Ozaltin F, Yilmaz E, Ozen S, Balci B, Besbas N, Bakkaloglu A. E148Q is a disease-causing MEFV mutation: a phenotypic evaluation in patients with familial Mediterranean fever. Ann Rheum Dis 2005;(64):750-2.
  • 26. Balci B, Tinaztepe K, Yilmaz E, Guçer S, Ozen S, Topaloğlu R, et al. MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol Dial Transplant 2002;(17):1921-3.
  • 27. Uluca Ü, Ece A, Şen V, Coşkun S, Güneş A, Yel S, et al. High frequency of E148Q sequence variation in children with familial Mediterranean fever in southeast Turkey. Arch Argent Pediatr 2015;(113):133-9.
  • 28. Yilmaz, E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, et al. Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001;(9):553-5.
  • 29. Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, Sohar E, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum 1996;(26):612-27.
  • 30. Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 2007;(37):182-8.
  • 31. Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology 2004;(43):410-5.
  • 32. Simms RW, Prout MN, Cohen AS.The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 1994;(8):627-34.
  • 33. Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 2014;(6):369-77.
  • 34. Gertz MA, Kyle RA. Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine 1991;(70):246-56.
  • 35. Wakhlu A, Krisnani N, Hissaria P, Aggarwal A, Misra R. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 2003;(30):948-51.
  • 36. Dhillon V, Woo P, Isenberg D. Amyloidosis in the rheumatic diseases. Ann Rheum Dis 1989;(48):696-701.
  • 37. Jayson MI, Salmon PR, Harrison W Amyloidosis in ankylosing spondylitis. Rheumatol Phys Med 1971;(11):78-82.
  • 38. Gratacos J, Orellana C, Sanmarti R, Sole M, Collado A, Gomez-Casanovas E, et al. Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 1997;(24):912-5.
  • 39. Paydas S. Report on 59 patients with renal amyloidosis. Int Urol Nephrol 1999;(31):619-31.
  • 40. Abdullah E, Waked E. Incidence and clinical outcome of renal amyloidosis: a retrospective study. Saudi J Kidney Dis Transpl 2013;(24):950-8.
  • 41. Hazenberg BPC, Van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 1994;(8):661-90.
  • 42. Tang W, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, et al. Endstage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases Nephrol Dial Transplant 2013;(28):455-61.
  • 43. Martinez-Vea A, Garcia C, Carreas M, Revert L, Oliver JA. End stage renal disease in systemic amyloidosis: clinical course and outcome on dialysis. Am J Nephrol 1990;(10):283-9.
  • 44. Sherif AM, Refaie AF, Sobh MA, Mohamed NA, Sheashaa HA, Ghoneim MA. Long term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kindey Dis 2003;(42):370-5.
  • 45. Haq A, Hussain S, Meskat B, Mohan P, Conlon P, Hickey DP. Complications of renal transplantation in patients with amyloidosis. Transplant Proc 2007;(39):120-4.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.